Evidence map›Paper›PMID 31511084›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance.

So-Yeon Park, Choong-Jae Lee, Jang-Hyun Choi, Jee-Heun Kim, Ji-Won Kim, Ji-Young Kim, Jeong-Seok Nam

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed, 2 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

189 citing papers in PubMed, 2 syntheses or guidelines pooled it, 307 citations in OpenAlex.

  1. Pooled it
  2. Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.International journal of molecular sciences · 2021
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

So-Yeon ParkSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea.
Choong-Jae LeeSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea.
Jang-Hyun ChoiSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea.
Jee-Heun KimSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea.
Ji-Won KimSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea.
Ji-Young KimSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea.
Jeong-Seok NamSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, 61005, Republic of Korea. namje@gist.ac.kr.
Gwangju Institute of Science and Technology · KR

Funding

Gwangju Institute of Science and Technology GRIMinistry of Science, ICT and Future Planning No. NRF-2017R1E1A1A01075125Ministry of Science, ICT and Future Planning NRF-2016R1A5A1007318
6 · The paper itself

Abstract

backgroundRadiotherapy (RT) is a highly effective multimodal nonsurgical treatment that is essential for patients with advanced colorectal cancer (CRC). Nevertheless, cell subpopulations displaying intrinsic radioresistance survive after RT. The reactivation of their proliferation and successful colonization at local or distant sites may increase the risk of poor clinical outcomes. Recently, radioresistant cancer cells surviving RT were reported to exhibit a more aggressive phenotype than parental cells, although the underlying mechanisms remain unclear.

methodsBy investigating public databases containing CRC patient data, we explored potential radioresistance-associated signaling pathways. Then, their mechanistic roles in radioresistance were investigated through multiple validation steps using patient-derived primary CRC cells, human CRC cell lines, and CRC xenografts.

resultsJanus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling was activated in radioresistant CRC tissues in correlation with local and distant metastases. JAK2 was preferentially overexpressed in the CRC stem cell subpopulation, which was accompanied by the phosphorylation of STAT proteins, especially STAT3. JAK2/STAT3 signaling played an essential role in promoting tumor initiation and radioresistance by limiting apoptosis and enhancing clonogenic potential. Mechanistically, the direct binding of STAT3 to the cyclin D2 (CCND2) promoter increased CCND2 transcription. CCND2 expression was required for persistent cancer stem cell (CSC) growth via the maintenance of an intact cell cycle and proliferation with low levels of DNA damage accumulation.

conclusionHerein, we first identified JAK2/STAT3/CCND2 signaling as a resistance mechanism for the persistent growth of CSCs after RT, suggesting potential biomarkers and regimens for improving outcomes among CRC patients.

Indexed as

Radiation ToleranceSignal TransductionCell Line, TumorColorectal NeoplasmsCyclin D2Gene Knockout TechniquesHumansHyaluronan ReceptorsJanus Kinase 2Models, BiologicalNeoplastic Stem CellsSTAT3 Transcription FactorCCND2 protein, humanCD44v6 antigenCyclin D2Hyaluronan ReceptorsJAK2 protein, humanJanus Kinase 2STAT3 protein, humanSTAT3 Transcription FactorCancer stem cells (CSCs)Colorectal cancer (CRC)Cyclin D2 (CCND2)Janus kinase 2 (JAK2)RadioresistanceSignal transducer and activator of transcription 3 (STAT3)

Identifiers

PMID31511084
PMCPMC6737692
OpenAlexW2972396522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.